{"id":48442,"date":"2025-11-17T14:46:07","date_gmt":"2025-11-17T06:46:07","guid":{"rendered":"https:\/\/flcube.com\/?p=48442"},"modified":"2025-11-17T14:46:08","modified_gmt":"2025-11-17T06:46:08","slug":"hangzhou-bio%e2%80%91sincerity-pharma%e2%80%91tech-secures-nmpa-approval-for-bios2242-oral-solution-in-acute-ischemic-stroke","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=48442","title":{"rendered":"Hangzhou Bio\u2011Sincerity Pharma\u2011Tech Secures NMPA Approval for BIOS2242 Oral Solution in Acute Ischemic Stroke"},"content":{"rendered":"\n<p><strong>Hangzhou Bio\u2011Sincerity Pharma\u2011Tech Corp., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/301096:SHE\">SHE: 301096<\/a>) announced that its <strong>BIOS2242 oral solution<\/strong> has received <strong>clinical\u2011trial approval<\/strong> from the <strong>China National Medical Products Administration (NMPA)<\/strong> for the treatment of <strong>mild to moderate acute ischemic stroke<\/strong>. The drug is classified as a <strong>Category\u202f2.2 modified product<\/strong>, designed specifically for patients who cannot safely swallow solid oral dosage forms.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Hangzhou Bio\u2011Sincerity Pharma\u2011Tech Corp., Ltd. (SHE: 301096)<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>BIOS2242 oral solution (Category\u202f2.2 modified drug)<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Mild\u2011to\u2011moderate acute ischemic stroke<\/td><\/tr><tr><td><strong>Regulatory Body<\/strong><\/td><td>China NMPA<\/td><\/tr><tr><td><strong>Approval Type<\/strong><\/td><td>Clinical\u2011trial (Phase\u202fI\/II) authorization \u2013 17\u202fNov\u202f2025<\/td><\/tr><tr><td><strong>Target Population<\/strong><\/td><td>Patients with cerebral ischemia who experience dysphagia, coma, impaired consciousness, paralysis or limb numbness<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-why-an-oral-solution-matters\">Why an Oral Solution Matters<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Dysphagia\u2011Friendly<\/strong> \u2013 Stroke patients often lose the ability to swallow tablets or capsules. An aqueous solution eliminates the risk of aspiration and ensures accurate dosing.<\/li>\n\n\n\n<li><strong>Rapid Onset<\/strong> \u2013 Liquid formulations can be absorbed more quickly than solid forms, a critical advantage in the narrow therapeutic window of acute ischemic stroke.<\/li>\n\n\n\n<li><strong>Simplified Administration<\/strong> \u2013 Caregivers can deliver the medication via syringe or feeding tube without the need for tablet crushing or compounding.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-amp-clinical-impact\">Market &amp; Clinical Impact<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Unmet Need<\/strong> \u2013 In China, >\u202f2\u202fmillion new ischemic\u2011stroke cases are reported annually; roughly <strong>30\u202f%<\/strong> present with swallowing difficulties that limit conventional oral therapy.<\/li>\n\n\n\n<li><strong>Revenue Potential<\/strong> \u2013 Assuming a <strong>10\u202f% market capture<\/strong> of the dysphagic stroke segment (\u2248\u202f600,000 patients) at an average price of <strong>CNY\u202f12,000<\/strong> per treatment course, BIOS2242 could generate <strong>\u2248\u202fCNY\u202f7.2\u202fbillion<\/strong> (~US$1.0\u202fbillion) in annual sales once fully commercialized.<\/li>\n\n\n\n<li><strong>Strategic Fit<\/strong> \u2013 The approval strengthens Hangzhou Bio\u2011Sincerity\u2019s pipeline in neuro\u2011vascular therapeutics and positions the company for future <strong>Phase\u202fIII<\/strong> expansion and potential <strong>global partnership<\/strong> discussions.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-forward-looking-statements\">Forward\u2011Looking Statements<\/h3>\n\n\n\n<p>This brief contains forward\u2011looking statements regarding regulatory timelines, market size, and revenue expectations for BIOS2242. Actual results may differ due to clinical outcomes, additional regulatory requirements, and competitive dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Hangzhou Bio\u2011Sincerity Pharma\u2011Tech Corp., Ltd. (SHE: 301096) announced that its BIOS2242 oral solution has received&#8230;<\/p>\n","protected":false},"author":1,"featured_media":48443,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[4372,62,3975],"class_list":["post-48442","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-biosincerity","tag-clinical-trial-approval-initiation","tag-she-301096"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Hangzhou Bio\u2011Sincerity Pharma\u2011Tech Secures NMPA Approval for BIOS2242 Oral Solution in Acute Ischemic Stroke - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Hangzhou Bio\u2011Sincerity Pharma\u2011Tech Corp., Ltd. (SHE: 301096) announced that its BIOS2242 oral solution has received clinical\u2011trial approval from the China National Medical Products Administration (NMPA) for the treatment of mild to moderate acute ischemic stroke. The drug is classified as a Category\u202f2.2 modified product, designed specifically for patients who cannot safely swallow solid oral dosage forms.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=48442\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Hangzhou Bio\u2011Sincerity Pharma\u2011Tech Secures NMPA Approval for BIOS2242 Oral Solution in Acute Ischemic Stroke\" \/>\n<meta property=\"og:description\" content=\"Hangzhou Bio\u2011Sincerity Pharma\u2011Tech Corp., Ltd. (SHE: 301096) announced that its BIOS2242 oral solution has received clinical\u2011trial approval from the China National Medical Products Administration (NMPA) for the treatment of mild to moderate acute ischemic stroke. The drug is classified as a Category\u202f2.2 modified product, designed specifically for patients who cannot safely swallow solid oral dosage forms.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=48442\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-17T06:46:07+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-17T06:46:08+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1707.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48442#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48442\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Hangzhou Bio\u2011Sincerity Pharma\u2011Tech Secures NMPA Approval for BIOS2242 Oral Solution in Acute Ischemic Stroke\",\"datePublished\":\"2025-11-17T06:46:07+00:00\",\"dateModified\":\"2025-11-17T06:46:08+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48442\"},\"wordCount\":329,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48442#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/1707.webp\",\"keywords\":[\"Bio\u2011Sincerity\",\"Clinical trial approval \\\/ initiation\",\"SHE: 301096\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=48442#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48442\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=48442\",\"name\":\"Hangzhou Bio\u2011Sincerity Pharma\u2011Tech Secures NMPA Approval for BIOS2242 Oral Solution in Acute Ischemic Stroke - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48442#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48442#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/1707.webp\",\"datePublished\":\"2025-11-17T06:46:07+00:00\",\"dateModified\":\"2025-11-17T06:46:08+00:00\",\"description\":\"Hangzhou Bio\u2011Sincerity Pharma\u2011Tech Corp., Ltd. (SHE: 301096) announced that its BIOS2242 oral solution has received clinical\u2011trial approval from the China National Medical Products Administration (NMPA) for the treatment of mild to moderate acute ischemic stroke. The drug is classified as a Category\u202f2.2 modified product, designed specifically for patients who cannot safely swallow solid oral dosage forms.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48442#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=48442\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48442#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/1707.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/1707.webp\",\"width\":1080,\"height\":608,\"caption\":\"Hangzhou Bio\u2011Sincerity Pharma\u2011Tech Secures NMPA Approval for BIOS2242 Oral Solution in Acute Ischemic Stroke\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48442#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Hangzhou Bio\u2011Sincerity Pharma\u2011Tech Secures NMPA Approval for BIOS2242 Oral Solution in Acute Ischemic Stroke\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Hangzhou Bio\u2011Sincerity Pharma\u2011Tech Secures NMPA Approval for BIOS2242 Oral Solution in Acute Ischemic Stroke - Insight, China&#039;s Pharmaceutical Industry","description":"Hangzhou Bio\u2011Sincerity Pharma\u2011Tech Corp., Ltd. (SHE: 301096) announced that its BIOS2242 oral solution has received clinical\u2011trial approval from the China National Medical Products Administration (NMPA) for the treatment of mild to moderate acute ischemic stroke. The drug is classified as a Category\u202f2.2 modified product, designed specifically for patients who cannot safely swallow solid oral dosage forms.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=48442","og_locale":"en_US","og_type":"article","og_title":"Hangzhou Bio\u2011Sincerity Pharma\u2011Tech Secures NMPA Approval for BIOS2242 Oral Solution in Acute Ischemic Stroke","og_description":"Hangzhou Bio\u2011Sincerity Pharma\u2011Tech Corp., Ltd. (SHE: 301096) announced that its BIOS2242 oral solution has received clinical\u2011trial approval from the China National Medical Products Administration (NMPA) for the treatment of mild to moderate acute ischemic stroke. The drug is classified as a Category\u202f2.2 modified product, designed specifically for patients who cannot safely swallow solid oral dosage forms.","og_url":"https:\/\/flcube.com\/?p=48442","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-11-17T06:46:07+00:00","article_modified_time":"2025-11-17T06:46:08+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1707.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=48442#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=48442"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Hangzhou Bio\u2011Sincerity Pharma\u2011Tech Secures NMPA Approval for BIOS2242 Oral Solution in Acute Ischemic Stroke","datePublished":"2025-11-17T06:46:07+00:00","dateModified":"2025-11-17T06:46:08+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=48442"},"wordCount":329,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=48442#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1707.webp","keywords":["Bio\u2011Sincerity","Clinical trial approval \/ initiation","SHE: 301096"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=48442#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=48442","url":"https:\/\/flcube.com\/?p=48442","name":"Hangzhou Bio\u2011Sincerity Pharma\u2011Tech Secures NMPA Approval for BIOS2242 Oral Solution in Acute Ischemic Stroke - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=48442#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=48442#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1707.webp","datePublished":"2025-11-17T06:46:07+00:00","dateModified":"2025-11-17T06:46:08+00:00","description":"Hangzhou Bio\u2011Sincerity Pharma\u2011Tech Corp., Ltd. (SHE: 301096) announced that its BIOS2242 oral solution has received clinical\u2011trial approval from the China National Medical Products Administration (NMPA) for the treatment of mild to moderate acute ischemic stroke. The drug is classified as a Category\u202f2.2 modified product, designed specifically for patients who cannot safely swallow solid oral dosage forms.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=48442#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=48442"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=48442#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1707.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1707.webp","width":1080,"height":608,"caption":"Hangzhou Bio\u2011Sincerity Pharma\u2011Tech Secures NMPA Approval for BIOS2242 Oral Solution in Acute Ischemic Stroke"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=48442#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Hangzhou Bio\u2011Sincerity Pharma\u2011Tech Secures NMPA Approval for BIOS2242 Oral Solution in Acute Ischemic Stroke"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1707.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/48442","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=48442"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/48442\/revisions"}],"predecessor-version":[{"id":48444,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/48442\/revisions\/48444"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/48443"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=48442"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=48442"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=48442"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}